BGB-A317-314
Active, not recruiting
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Study Overview
Sex:
All 
Age: 18 Years / N/A
No Study Documents
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents